Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, Ottevanger PB, Bloemendal HJ, Koolen SLW, Mathijssen RHJ, Boere IA, Hamberg P, Huitema ADR, Sonke GS, Opdam FL, Ter Heine R, van Erp NP. Overbeek JK, et al. Among authors: ottevanger pb. Eur J Cancer. 2023 Nov;194:113346. doi: 10.1016/j.ejca.2023.113346. Epub 2023 Sep 19. Eur J Cancer. 2023. PMID: 37806255 Free article. Clinical Trial.
EORTC-GCG process quality indicators for ovarian cancer surgery.
Verleye L, Ottevanger PB, van der Graaf W, Reed NS, Vergote I; Gynaecological Cancer Group (GCG) of European Organisation for Research and Treatment of Cancer (EORTC). Verleye L, et al. Among authors: ottevanger pb. Eur J Cancer. 2009 Mar;45(4):517-26. doi: 10.1016/j.ejca.2008.09.031. Epub 2008 Nov 14. Eur J Cancer. 2009. PMID: 19013789 Review.
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial.
Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, Reed NS, Verheijen RH, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I. Verleye L, et al. Among authors: ottevanger pb. Eur J Cancer. 2011 Jan;47(1):57-64. doi: 10.1016/j.ejca.2010.08.008. Epub 2010 Sep 16. Eur J Cancer. 2011. PMID: 20850296 Clinical Trial.
Rationale of the BREAst cancer e-healTH [BREATH] multicentre randomised controlled trial: an internet-based self-management intervention to foster adjustment after curative breast cancer by decreasing distress and increasing empowerment.
van den Berg SW, Gielissen MF, Ottevanger PB, Prins JB. van den Berg SW, et al. Among authors: ottevanger pb. BMC Cancer. 2012 Sep 7;12:394. doi: 10.1186/1471-2407-12-394. BMC Cancer. 2012. PMID: 22958799 Free PMC article. Clinical Trial.
Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
Boers-Sonderen MJ, de Geus-Oei LF, Desar IM, van der Graaf WT, Oyen WJ, Ottevanger PB, van Herpen CM. Boers-Sonderen MJ, et al. Among authors: ottevanger pb. Target Oncol. 2014 Dec;9(4):339-47. doi: 10.1007/s11523-014-0309-x. Epub 2014 Mar 1. Target Oncol. 2014. PMID: 24577626 Clinical Trial.
Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).
Boers-Sonderen MJ, van Herpen CM, van der Graaf WT, Desar IM, van der Logt MG, de Beer YM, Ottevanger PB, van Erp NP. Boers-Sonderen MJ, et al. Among authors: ottevanger pb. Cancer Chemother Pharmacol. 2014 Sep;74(3):457-63. doi: 10.1007/s00280-014-2514-9. Epub 2014 Jun 26. Cancer Chemother Pharmacol. 2014. PMID: 24965180 Clinical Trial.
148 results